Biomerieux SA
PAR:BIM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
88.75
110.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Biomerieux SA
Biomerieux SA
Total Equity
Biomerieux SA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomerieux SA
PAR:BIM
|
Total Equity
€3.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
12%
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Total Equity
€56.9m
|
CAGR 3-Years
30%
|
CAGR 5-Years
18%
|
CAGR 10-Years
20%
|
|
|
Carmat SA
PAR:ALCAR
|
Total Equity
-€22.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-24%
|
|
|
Biosynex SA
PAR:ALBIO
|
Total Equity
€103.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
28%
|
CAGR 10-Years
40%
|
|
|
Visiomed Group SA
PAR:ALVMG
|
Total Equity
€24.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
132%
|
CAGR 10-Years
16%
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Total Equity
€95.8m
|
CAGR 3-Years
18%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Biomerieux SA
Glance View
Show Overview: BioMérieux SA: Pioneering Diagnostics for a Healthier World BioMérieux SA, a French multinational founded in 1963, stands at the forefront of the global diagnostics industry, driving innovation in infectious disease testing and food safety. With a mission to improve public health through advanced diagnostic solutions, the company has developed a robust portfolio of products that include molecular biology, microbiology, and immunoassays. Its cutting-edge technologies empower healthcare professionals to detect pathogens with speed and accuracy, making a direct impact on patient outcomes and aiding in the prevention of disease outbreaks. By continuously investing in research and development, BioMérieux not only maintains its competitive edge but also expands its reach in emerging markets, balancing its operations with a strong commitment to sustainability and social responsibility. As health crises grow more complex and interconnected, BioMérieux's efforts to enhance diagnostic capacity have never been more critical. The company's recent forays into automation and artificial intelligence signal a shift toward more integrated and efficient testing systems, equipping laboratories and healthcare providers worldwide with the tools necessary to meet rising healthcare demands. Investors can see the potential for substantial returns not only through BioMérieux's innovative product offerings but also through its strategic partnerships and global expansion initiatives. With a solid financial foundation and a vision anchored in improving patient care, BioMérieux represents a compelling opportunity for investors looking to align with a company dedicated to making a meaningful difference in the health of communities across the globe.
See Also
What is Biomerieux SA's Total Equity?
Total Equity
3.9B
EUR
Based on the financial report for Jun 30, 2024, Biomerieux SA's Total Equity amounts to 3.9B EUR.
What is Biomerieux SA's Total Equity growth rate?
Total Equity CAGR 10Y
12%
Over the last year, the Total Equity growth was 7%. The average annual Total Equity growth rates for Biomerieux SA have been 13% over the past three years , 13% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet
